Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy

9 April 2024 Off By Bambam

Nature, Published online: 08 April 2024; doi:10.1038/s41586-024-07205-6

RMC-7977, a compound that exhibits potent inhibition of the active states of mutant and wild-type KRAS, NRAS and HRAS variants has a strong anti-tumour effect on RAS-addicted tumours and is well tolerated in preclinical models.